Based on the possible crosstalk between CypA/CD147 and EGFR, we assessed the effects of the combined treatment with CypA inhibitors and afatinib on the growth of NSCLC-derived CSCs using concentrations below the IC30 value of each compound. This evidence concerns the gene EGFR and non-small cell lung carcinoma.